Tuesday | Wednesday | Thursday | Friday | Saturday
WEDNESDAY, DECEMBER 5, 2018
7:00 am - 5:15 pm Registration - Main Lobby  
     
7:00 am - 8:00 am Continental Breakfast - Hall 2  
     
8:00 am - 8:15 am WELCOME AND OPENING REMARKS – Hall 3
C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX
 
     
8:15 am - 8:45 am PLENARY LECTURE 1 - Hall 3  

Breast Tumor Evolution and Intratumor Heterogeneity - Insights from Single Cell Genomics 
Nicholas E. Navin, PhD
UT MD Anderson Cancer Center
Houston, TX
 
                            
8:45 am - 11:15 am

GENERAL SESSION 1 – Hall 3
Moderator: Christos Sotiriou, MD, PhD
Institut Jules Bordet
Brussels, BELGIUM

 
     
8:45 am GS1-01.  Landscape of the breast tumour microenvironment at single-cell resolution
 
                           Swarbrick A, Wu SZ, Roden D, Al-Eryani G, O'Toole S, Lim E. Garvan Institute, Sydney, New South Wales, Australia; St. Vincents Clinical School, UNSW Sydney, Sydney, New South Wales, Australia.  
     
9:00 am

GS1-02. Towards a human breast cell atlas

 
                           Seth TK, Bai S, Hu M, Sei E, Wood A, Wiley J, Chen H, Contreras A, Teshome M, Lim B, Navin NE.  The University of Texas MD Anderson Cancer Center, Houston, TX.
 
 
9:15 am GS1-03. Crosstalk between osteoblasts and breast cancer cells alters breast cancer proliferation through multiple mechanisms  
  Bussard KM, Shupp AB, Kolb AD, Mukhopdhyay D.  Thomas Jefferson University, Philadelphia, PA.  
     
 9:30 am GS1-04. IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer  
  Emens LA, Loi S, Rugo HS, Schneeweiss A, Diéras V, Iwata H, Barrios CH, Nechaeva M, Molinero L, Nguyen Duc A, Funke R, Chui SY, Husain A, Winer EP, Adams S, Schmid P. Bloomberg∼Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; University Hospital Heidelberg, Heidelberg, Germany; Centre Eugène Marquis, Rennes, France; Aichi Cancer Center Hospital, Aichi, Japan; PUCRS School of Medicine, Porto Alegre, Brazil; Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russian Federation; Genentech, Inc., South San Francisco, CA; Roche AG, Basel, Switzerland; Dana-Farber Cancer Institute, Boston, MA; New York University Langone Medical Center, New York, NY; Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.   
     
9:45 am

GS1-05. Apobec3 induced mutagenesis sensitizes murine models of triple negative breast cancer to immunotherapy by activating B-cells and CD4+ T-cells

 
  Hollern DP, Xu N, Mott KR, He X, Carey-Ewend K, Marron DS, Ford J, Parker JS, Vincent BG, Serody JS, Perou CM.  University of North Carolina, Chapel Hill, NC.
 
     
10:00 am GS1-06. Unraveling lobular breast cancer progression and endocrine resistance mechanisms through genomic and immune characterization of matched primary and metastatic samples
 
  Desmedt C, Richard F, Majjaj S, Pingitore J, Brown D, Rothé F, Marchio C, Clatot F, Mariani O, Boeckx B, Rouas G, Bertucci F, Galant C, Van den Eynden G, Salgado R, Lambrechts D, Vincent-Salomon A, Piccart M, Pruneri G, Larsimont D, Sotiriou C.  Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium; MSKCC, New York; University of Turin, Candiolo, Italy; Centre Henri-Becquerel, Rouen, France; Institut Curie, Paris, France; VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium; Institut Paoli-Calmettes, Marseilles, France; Cliniques Universitaires Saint Luc, Brussels, Belgium; Sint Augustinus, Wilrijk, Belgium; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.  
     
10:15 am GS1-07.  The genomic landscape of 501 metastatic breast cancer patients
 
                           Angus L, Wilting SM, van Riet J, Smid M, Steenbruggen TG, Tjan-Heijnen VC, Labots M, van Riel JM, Bloemendal HJ, Steeghs N, van de Werken HJ, Lolkema MP, Voest EE, Jager A, Cuppen E, Sleijfer S, Martens JW.  Erasmus MC Cancer Institute, Erasmus University, Rotterdam, Netherlands; Cancer Computational Biology Center, Erasmus MC Cancer Institute, Erasmus University, Rotterdam, Netherlands; The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, Netherlands; GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, Netherlands; Cancer Center Amsterdam, VU University Medical Center, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Meander Medical Center, Amersfoort, Netherlands; Center for Personalized Cancer Treatment, Rotterdam, Netherlands; Center for Molecular Medicine and Oncode Institute, University Medical Center Utrecht, Utrecht, Netherlands; Hartwig Medical Foundation, Amsterdam, Netherlands.  
     
 10:30 am GS1-08 Genomic characterisation of metastatic breast cancer  
  Andre F, Filleron T, Ng C, Bertucci F, Letourneau C, Jacquet A, Piscuoglio S, Jimenez M, Bachelot T.  Institut Gustave Roussy, Villejuif, France; Centre Claudius Regaut, Toulouse, France; University of Basel, Basel, Switzerland; Institut Curie, Paris, France; Institut Paoli Calmette, Marseille, France; UNICANCER, Paris, France; Centre Leon Berard, Lyon, France.  
     
 10:45 am GS1-09 Discussant  
  Nikhil Wagle, MD
Dana-Farber Cancer Institute
Boston, MA
 
     
 11:00 am GS1-10 Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: primary results from KATHERINE  
  Geyer Jr. CE, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Fischer HH, Redondo A, Jackisch C, Jacot W, Conlin AK, Schneeweiss A, Wapnir IL, Fasching PA, DiGiovanna MP, Wuelfing P, Arce-Salinas C, Crown JP, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, von Minckwitz G.  Virginia Commonwealth University Massey Cancer Center, Richmond, VA; National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil; German Breast Group (GBG), Neu-Isenberg, Germany; Orlando Health University of Florida Health Cancer Center, Orlando, FL; HELIOS Klinikum Berlin Buch, Berlin, Germany; Centre for Haematology and Oncology Bethanien, Frankfurt, Germany; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, PA; National Cancer Institute, Mexico City, Mexico; Sana Klinikum Offenbach, Offenbach, Germany; Irish Cooperative Oncology Research Group, Dublin, Ireland; Providence Portland Medical Center, Portland, OR; Fudan University Shanghai Cancer Center, Shanghai, China; Stanford University School of Medicine, Stanford, CA; Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bavaria, Germany; Yale School of Medicine, Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT; Mammazentrum Hamburg Krankenhaus Jerusalem, Hamburg, Germany; Cancer Center ASST Papa Giovanni XXIII, Bergamo, Italy; Hospital Universitario La Paz – IdiPAZ, Madrid, Spain; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; F. Hoffman-La Roche Ltd. China Holding Ltd., Shanghai, China; Genentech, Inc., South San Francisco, CA; F. Hoffman-La Roche Ltd., Welwyn Garden City, United Kingdom;University of Pittsburgh Cancer Institute School of Medicine, Pittsburgh, PA; Evangelische Kliniken Gelsenkirchen, Gelsenkirchen, Germany; Institut Régional du Cancer de Montpellier, Montpellier University, INSERM U1194 – IRCM Montpellier, France; German Gynecological Oncology Working Group-Breast (AGO-B), Frankfurt, Germany.  
     
11:15 am - 12:00 pm WILLIAM L. MCGUIRE MEMORIAL LECTURE - Hall 3  
 

Hold That Scalpel! Using the Tumor to Determine the Treatment
Ian E. Smith, MD, FRCP, FRCPE
The Royal Marsden NHS Foundation Trust
London, UNITED KINGDOM

 
     
12:00 pm - 1:00 pm BREAK  
     
12:00 pm - 1:00 pm  CAREER DEVELOPMENT FORUM - Room 304
Limited to 200 participants; registrations will be accepted on a first-come, first-served basis and are free of charge.  Badges are required and will be scanned at door for registration.
Attendees should prepare to visit 3-4 tables during the session.  Attendees will be asked to rotate tables every 20 minutes.
 
  Introduction Discussion
12:00 ‐12:05 p.m.   
Yi Li, PhD, Baylor College of Medicine, Houston, TX  

Mentoring Roundtables
12:05 ‐1:00 p.m.  
1. Balancing Research and Clinical Practice
Andrea V. Barrio, MD, Memorial Sloan Kettering Cancer Center, New York, NY
Mothaffar F. Rimawi, MD, Baylor College of Medicine, Houston, TX

2. Becoming a Successful Clinical Trialist
Hope S. Rugo, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Priyanka Sharma, MD, Associate Professor, University of Kansas Medical Center, Kansas City, KS  

3. Careers in Industry 
Lori Friedman, PhD, Genentech, Inc., South San Francisco, CA 
  
4. Careers in Translational Research
Judy C. Boughey, MD, Mayo Clinic, Rochester, MN
Shom Goel, B Med Sci, MBBS, FRACP, PhD, Dana-Farber Cancer Institute, Boston, MA
    
5. Grant Writing
Susan G. Hilsenbeck, PhD, Baylor College of Medicine, Houston, TX
Nicholas E. Navin, PhD, UT MD Anderson Cancer Center, Houston, TX  

6.  Mentor-Mentee Relationships
 Debra Patt, MD, MPH, Texas Oncology, Austin, TX
 Michael Lewis, PhD, Baylor College of Medicine, Houston, TX  

7. Making the Transition from Fellowship to Faculty
Pepper J. Schedin, PhD, Oregon Health & Science University Hospital, Portland, OR
Xiang Zhang, PhD, Baylor College of Medicine, Houston, TX  

8. Negotiating a Job Offer or Promotion
Reshma Jagsi, MD, DPhil, University of Michigan, Ann Arbor, MI
Alex Toker, PhD, Beth Israel Deaconess Medical Center, Boston, MA  

9. How to Build Collaborations
Matthew P. Goetz, MD, Mayo Clinic, Rochester, MN
Patricia S. Steeg, PhD, National Cancer Institute, Bethesda, MD
10. Transitioning to a Research Position in the U.S.
Mikala Egeblad, PhD, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
Yi Li, PhD, Baylor College of Medicine, Houston, TX  

11. Publication Strategies: Quality vs. Quantity
Roisin M. Connolly, MBBCh, MD, Johns Hopkins School of Medicine, Baltimore, MD
Eric P. Winer, MD, Dana-Farber Cancer Institute, Boston, MA
 
     
1:00 pm - 2:00 pm CLINICAL SCIENCE FORUM - Stars at Night Ballroom 1&2 - 3rd Level  
 

Cancer Genetics: Updates for Breast Cancer Care
Moderator: Judy E. Garber, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Polygenic risk scores for breast cancer: Ready or not?
D. Gareth Evans, FRCP, MD, MBBS
University of Manchester
Manchester, UNITED KINGDOM

Breast cancer genetic testing and results in diverse populations
Allison W. Kurian, MD, MSc
Stanford University School of Medicine
Stanford, CA

Moderate penetrance mutations: What to do?
Susan M. Domchek, MD
University of Pennsylvania
Philadelphia, PA

 
     
1:00 pm - 2:00 pm BASIC SCIENCE FORUM 1 - Stars at Night Ballroom 3&4 - 3rd Level  
 

Peering into Tumor-Microenvironment Interaction in Metastasis
Moderator: Yi Li, PhD
Baylor College of Medicine
Houston, TX

High resolution intravital imaging of the mechanism of how breast cancer initiates and sustains systemic dissemination
John S. Condeelis, PhD
Albert Einstein College of Medicine
Bronx, NY

Neutrophil extracellular traps promote breast cancer metastasis
Mikala Egeblad, PhD
Cold Spring Harbor Laboratory
Cold Spring Harbor, NY

New insights into early-stage bone colonization of disseminated breast cancer cells
Xiang Zhang, PhD
Baylor College of Medicine
Houston, TX

 
  

2:15 pm - 3:15 pm

SUSAN G. KOMEN® BRINKER AWARDS FOR SCIENTIFIC DISTINCTION LECTURES – Hall 3

 
  SUSAN G. KOMEN® BRINKER AWARD FOR SCIENTIFIC DISTINCTION IN BASIC SCIENCE 
Modeling Immune Response: Lessons Learned from Mouse Models of Cancer Development
Lisa Coussens, PhD
Oregon Health & Sciences University
Portland, OR
 
  SUSAN G. KOMEN® BRINKER AWARD FOR SCIENTIFIC DISTINCTION IN CLINICAL RESEARCH 
The Challenge of Doing Less
Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA
 
3:15 pm - 5:00 pm

GENERAL SESSION 2 – Hall 3
Moderator: Sara Hurvitz, MD
UCLA Medical Center
Santa Monica, CA

 
3:15 pm GS2-01. Age-related breast cancer risk estimates for the general population based on sequencing of cancer predisposition genes in 19,228 breast cancer patients and 20,211 matched unaffected controls from US based cohorts in the CARRIERS study  
                          

Couch FJ, Hu C, Hart SN, Gnanaolivu RD,Lilyquist J, Lee KY, Gao C, Eckloff B, Samara R, Klebba J, Auer P, Bernstein L, Gaudet M, Haiman C, Palmer JR, Yao S, Domchek SM, Weitzel JN, Goldgar DE, Nathanson KL, Kraft P, Polley EC.  Mayo Clinic, Rochester, MN; Harvard University, Cambridge, MA; Qiagen Inc., Washington, DC; University of Wisconsin-Milwaukee, Milwaukee, WI; City of Hope Cancer Institute, Duarte, CA; American Cancer Society, Atlanta, GA; University of Southern California, Los Angeles, CA; Boston University, Boston, MA; Roswell Park Cancer Center, Buffalo, NY; University of Pennsylvania, Philadelphia, PA; University of Utah, Salt Lake City, UT.

 
     
3:30 pm GS2-02. Efficacy and utilization trends of adjuvant chemotherapy for stage I, II, and III breast cancer in the elderly population: A National Cancer Database (NCDB) analysis  
  Sinha S, Panebianco L, Wu X, Wang D, Sivapiragasam A, Huang D.  SUNY Upstate Medical University, Syracuse, NY.  
     
3:45 pm GS2-03. Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality, stratified by breast cancer subtypes and adjuvant chemotherapy usage: Individual patient-level meta-analyses of over 27,000 patients
 
  Spring LM, Fell G, Arfe A, Trippa L, Greenup R, Reynolds K, Smith BL, Moy B, Isakoff SJ, Parmigiani G, Bardia A.  Massachusetts General Hospital Cancer Center, Boston, MA; Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA.  
     
4:00 pm  GS2-04. Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer
Martín M, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Ruiz A, García-Sáenz JA, Torres R, de la Haba J, García E, Gómez HL, Llombart A, Rodríguez de la Borbolla M, Baena JM, Barnadas A, Calvo L, Pérez-Michel L, Ramos M, Castellanos J, Rodríguez-Lescure Á, Cárdenas J, Vinholes J, Martínez de Dueñas E, Godes MJ, Seguí MA, Antón A, López-Álvarez P, Moncayo J, Amorim G, Villar E, Reyes S, Sampaio C, Cardemil B, Escudero MJ, Bezares S, Carrasco E, Lluch A.  Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio Marañón. Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain; Centro de Pesquisa Clínica Hospital São Lucas da PUCRS, Porto Alegre/RS, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre/RS, Brazil; Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico DF, Mexico; Hospital Universitario Virgen del Rocío, Seville, Spain; Instituto Nacional de Câncer (INCA) José Alencar Gomes da Silva, Rio de Janeiro, Brazil; Hospital Amaral Carvalho, Chácara Braz Miraglia, Jaú - SP, Brazil; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Clínico San Carlos, Madrid, Spain; Instituto Nacional del Cáncer, Santiago, Chile; Hospital Universitario Reina Sofía, Córdoba, Spain; Hospital General Universitario Morales Messeguer, Murcia, Spain; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; GECOPERU, Peruvian Oncological Clinical Studies Group, Lima, Peru; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Universitario Virgen de Valme, Sevilla, Spain; Hospital Universitario Puerta del Mar, Cádiz, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain; Hospital de San José, Ciudad Obregón. Sonora, Mexico; Centro Oncológico de Galicia, A Coruña, Spain; Complexo Hospitalario Universitario de Vigo (CHUVI), Vigo, Spain; Hospital General Universitario de Elche, Alicante, Spain; Centro Médico Colima, Colima Col., Mexico; Centro de Pesquisa Unidade de Novos Tratamentos CliniOnco, Porto Alegre, Brazil; Consorcio Hospitalario Provincial de Castellón, Castellón, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Corporació Sanitaria Parc Taulí de Sabadell, Barcelona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain; Hospital de Especialidades Teodoro Maldonado Carbo, Guayaquil, Ecuador; Oncologistas Associados - Oncologia D'Or Rio de Janeiro, Sao Paulo, Brazil; Hospital Regional Universitario Carlos Haya, Málaga, Spain; Hospital Beneficiencia Española, San Luis de Potosí, Mexico; Clínica Amo Itaigara, Salvador-BA, Brazil; Hospital Base de Valdivia, Valdivia, Región de los Ríos, Chile; Hospital Clínico Universitario de Valencia. Biomedical Research Institute INCLIVA. University of Valencia, Valencia, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.
 
     
4:15 pm GS2-05. Impact of the delayed initiation of adjuvant chemotherapy in the outcomes of triple negative breast cancer  
                           Morante Z, Ruiz R, De la Cruz - Ku G, Namuche F, Mantilla R, Lujan MG, Fuentes H, Schwarz J, Aguilar A, Neciosup S, Gomez H.  Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; ONCOSALUD - AUNA, Lima, Peru; Universidad Cientifica del Sur Lima, Peru.  
     
4:30 pm GS2-06. Discussant
Joseph Sparano, MD
Montefiore Medical Center
Bronx, NY
     
4:45 pm GS2-07. PHARE randomized trial final results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer  
  Pivot X, Romieu G, Debled M, Pierga J-Y, Kerbrat P, Bachelot T, Espie M, Lortholary A, Fumoleau P, Serin D, Jacquin J-P, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Venat-Bouvet L, Cany L, Catala S, Khayat D, Gambotti I, Pauporte I, Faure Mercier C, Paget-Bailly S, Henriques J, Grouin J-M.  Paul Strauss Cancer Center, Strasbourg, France; Val d'Aurelle cancer Center, Montpellier, France; Bergonie Cancer Center, Bordeaux, France; Curie Institut, Paris, France; Leon Berard Cancer Center, Lyon, France; Saint Louis University Hospital, Paris, France; Centre Catherine de Sienne, Nantes, France; Sainte Catherine Institut, Avignon, France; Lucien Neuwirth Cancer Institut, Saint Priest en Jarez, France; Jean Godinot Cancer Center, Reims, France; Alexis Vautrin Cancer Center, Nancy, France; Loire Cancer Institut, Anger, France; Limoges University Hospital, Limoges, France; Clinique Francheville, Perigueux, France; Clinique Saint Pierre, Perpignan, France; Clinique Bizet, Paris, France; French National Cancer Institut, Boulogne, France; Ligue Contre le Cancer, Paris, France; Eugene Marquis Cancer Center, Rennes, France; University Hospital J Minjoz, Besancon, France and University of Rouen Department of Statistic, Rouen, France.  
     
5:00 pm - 7:00 pm

Spotlight Session 1: Developmental Therapeutics – Stars at Night Ballroom 1&2 - 3rd Level

Chair: Matthew J. Ellis, MD, PhD
Baylor College of Medicine
Houston, TX

Discussants:

New treatments and targets for HER2- breast cancer
Foluso Ademuyiwa, MD
Washington University School of Medicine
St. Louis, MO

New treatments and targets for ER+ breast cancer
Claire Dees, MD
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, NC

 
                          
 
5:00 pm - 7:00 pm Spotlight Session 2: Biomarkers in Clinical Trials - Stars at Night Ballroom 3&4 - 3rd Level
Chair: Ben Park, MD, PhD
Vanderbilt University Medical Center,
Nashville, TN

Discussants:

Circulating biomarkers
Michail Ignatiadis, MD, PhD
Institute Jules Bordet
Brussels, BELGIUM

Tissue biomarkers
Andrea L. Richardson, MD/PhD
Johns Hopkins Medicine
Washington, DC

 
     
5:00 pm - 7:00 pm POSTER SESSION 1 & reception – Hall 1
 
     
 

Detection/Diagnosis

Radiology-Tumor Monitoring
Screening
Other

P1-01
P1-02
P1-03

     
 

Tumor Cell and Molecular Biology

Cell Cycle Regulation
Cellular Mechanisms
DNA Damage and Repair
Stem/Progenitor Cells

P1-04
P1-05
P1-06
P1-07

     
 

Epidemiology, Risk, and Prevention

Epidemiology-Population Studies
Genetic and Molecular Studies
Ethnic/Racial Aspects

P1-08
P1-09
P1-10

     
  Psychosocial, QOL, and Educational Aspects

QOL-Supportive Care
Survivorship Research


P1-11
P1-12
     
  Treatment

Adjuvant Chemotherapy
Advanced Chemotherapy
Neoadjuvant Chemotherapy
Advanced Therapy
Adjuvant Therapy - Other
Bone Metastases
Brain Mets
 

P1-13
P1-14
P1-15
P1-16
P1-17
P1-18
P1-19

     
  Rescheduled Abstracts P1-20
     
  Ongoing Trials

Endocrine Therapy
Endocrine Therapy - AR
Endocrine Resistance
DCIS
Chemotherapy
Chemotherapy - Brain Metastases
Chemotherapy - Cutaneous Metastases
Chemotherapy - Supportive Care
Neoadjuvant Chemotherapy Assessment
Circulating Tumor Cells
Biomarkers - Biobanking and Registries
Predictive Biomarkers
Genomic Signatures
 

OT1-01
OT1-02
OT1-03
OT1-04
OT1-05
OT1-06
OT1-07
OT1-08
OT1-09
OT1-10
0T1-11
OT1-12
OT1-13
     
7:30 pm - 9:30 pm

OPEN SATELLITE EVENT hosted by Clinical Care Options - Marriott Rivercenter

Advances in HR+/HER2- Metastatic Breast Cancer: Current Practice, Open Questions, and Future Directions
For more information and to register for this event, please click on the link below:

https://www.clinicaloptions.com/HRPositive2018

 
     
7:30 pm - 10:00 pm OPEN SATELLITE EVENT hosted by Prime Oncology - Marriott Rivercenter 

Triple-Negative Breast Cancer - Developing a More Positive Approach
For more information and to register for this event, please click on the link below:

https://www.primeoncology.org/live-events/oncology/triple-negative-breast-cancer-san-antonio-2018/

 
     
 
Tuesday | Wednesday | Thursday | Friday | Saturday
 

S1-04.

S1-04.

Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: primary results from KATHERINE
Limited to 200 participants; registrations will be accepted on a first-come, first-served basis and are free of charge. Badges are required and will be scanned at door for registration.   Attendees should prepare to visit 3-4 tables during the session. Attendees will be asked to rotate tables every 20 minutes.
Limited to 200 participants; registrations will be accepted on a first-come, first-served basis and are free of charge. Badges are required and will be scanned at door for registration.   Attendees should prepare to visit 3-4 tables during the session. Attendees will be asked to rotate tables every 20 minutes.
Limited to 200 participants; registrations will be accepted on a first-come, first-served basis and are free of charge. Badges are required and will be scanned at door for registration.   Attendees should prepare to visit 3-4 tables during the session. Attendees will be asked to rotate tables every 20 minutes.